KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Globus Medical (GMED) Research & Development (2016 - 2025)

Globus Medical's Research & Development history spans 15 years, with the latest figure at $36.2 million for Q4 2025.

  • For Q4 2025, Research & Development rose 8.25% year-over-year to $36.2 million; the TTM value through Dec 2025 reached $147.2 million, up 23.65%, while the annual FY2025 figure was $147.2 million, 10.08% down from the prior year.
  • Research & Development reached $36.2 million in Q4 2025 per GMED's latest filing, down from $38.1 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $52.3 million in Q4 2023 to a low of $12.6 million in Q1 2024.
  • Average Research & Development over 5 years is $28.0 million, with a median of $25.3 million recorded in 2023.
  • Peak YoY movement for Research & Development: surged 234.77% in 2021, then crashed 61.77% in 2022.
  • A 5-year view of Research & Development shows it stood at $51.0 million in 2021, then plummeted by 61.77% to $19.5 million in 2022, then skyrocketed by 167.86% to $52.3 million in 2023, then crashed by 36.06% to $33.4 million in 2024, then rose by 8.25% to $36.2 million in 2025.
  • Per Business Quant, the three most recent readings for GMED's Research & Development are $36.2 million (Q4 2025), $38.1 million (Q3 2025), and $40.0 million (Q2 2025).